HIG
63
7
CMCSA
46
4
INTU
56
-9
TRV
58
2
MAT
49
4
ABT
45
4
WEC
43
4
PEP
50
2
EIX
56
2
DTE
34
-4
AME
69
4
AZO
48
5
MUR
38
-6
FTI
78
-4
ALL
63
6
VMC
59
2
DAL
72
2
ETR
55
3
NWSA
71
-2
QRVO
46
-2
HIG
63
7
CMCSA
46
4
INTU
56
-9
TRV
58
2
MAT
49
4
ABT
45
4
WEC
43
4
PEP
50
2
EIX
56
2
DTE
34
-4
AME
69
4
AZO
48
5
MUR
38
-6
FTI
78
-4
ALL
63
6
VMC
59
2
DAL
72
2
ETR
55
3
NWSA
71
-2
QRVO
46
-2
Financhill
Back

Astellas Pharma, Inc. 10K Form

Buy
63

ALPMY
Astellas Pharma, Inc.

Last Price:
$13.65
Seasonality Move:
2.58%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ALPMY News And Ratings

See the #1 stock for the next 7 days that we like better than ALPMY

ALPMY Financial Statistics

Sales & Book Value

Annual Sales: $12.5B
Cash Flow: $1.4B
Price / Cash Flow: 10.54
Annual Sales: $6.10
Price / Book: 2.23

Profitability

EPS (TTM): 0.47840
Net Income (TTM): $861.2M
Gross Margin: $9.4B
Return on Equity: 8.36%
Return on Assets: 3.75%

Astellas Pharma, Inc. Earnings Forecast

Key Astellas Pharma, Inc. Financial Ratios

  • The Gross Profit Margin over the past 22 years for ALPMY is 74.59%.
  • The Selling, General & Administrative Expenses for ALPMY have been equal to 44.08% of Gross Profit Margin.
  • The Research & Development expenses have been 17.13% of Revenue.
  • The Interest Expense is 28.28% of Operating Income.
  • The Net Earning history of ALPMY is 2.65% of Total Revenues.
  • Per Share Earnings over the last 22 years have been positive in 11 years.

Astellas Pharma, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ALPMY
Website: astellas.com

Debt

Debt-to-Equity Ratio: 0.46
Current Ratio: 1.03
Quick Ratio: 0.75

Price-to-Earnings

Trailing P/E Ratio: 73.33
Forward P/E Ratio: 0

ALPMY Technical Analysis vs Fundamental Analysis

Buy
63
Astellas Pharma, Inc. (ALPMY) is a Buy

Is Astellas Pharma, Inc. a Buy or a Sell?